The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay.
 
Tuan Hoang
No Relationships to Disclose
 
Yahan Yang
No Relationships to Disclose
 
Sally Lau
No Relationships to Disclose
 
Miguel García-Pardo
No Relationships to Disclose
 
Collin Melton
Employment - Adela
Stock and Other Ownership Interests - Adela; Illumina
 
Justin Burgener
Employment - Adela
Stock and Other Ownership Interests - Adela
Patents, Royalties, Other Intellectual Property - Adela
 
Ben Brown
Employment - Adela
Leadership - Adela
Stock and Other Ownership Interests - Adela
 
Scott Bratman
Employment - Adela
Leadership - Adela
Stock and Other Ownership Interests - Adela
Consulting or Advisory Role - EMD Serono
Patents, Royalties, Other Intellectual Property - Co-inventor and holder of a patent related to circulating tumor DNA detection technology.; Co-inventor of patent application pending related to detection of HPV circulating cell-free DNA. (Inst); Co-inventor of patents related to cell-free DNA methylation analysis technology. (Inst)
 
Alan Williams
Employment - Adela
Leadership - Adela
Stock and Other Ownership Interests - Adela
 
Brian Allen
Employment - Adela
Stock and Other Ownership Interests - Adela; Illumina
 
Jing Zhang
Employment - Adela
Stock and Other Ownership Interests - Adela; Illumina
 
Daniel De Carvalho
Employment - Adela
Leadership - Adela
Stock and Other Ownership Interests - Adela
Patents, Royalties, Other Intellectual Property - Adela
 
Anne-Renee Hartman
Employment - Adela
Leadership - Adela
Stock and Other Ownership Interests - Adela
 
Lawson Eng
No Relationships to Disclose
 
Penelope Bradbury
Honoraria - OncologyEducation
Consulting or Advisory Role - RAPT Therapeutics
(OPTIONAL) Uncompensated Relationships - Abbvie; AstraZeneca; Bristol-Myers Squibb; Merck; Mirati Therapeutics
 
Frances Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Celltrion/Teva; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Natasha Leighl
Research Funding - AstraZeneca Canada (Inst); GlaxoSmithKline Canada (Inst); Guardant Health (Inst); Inivata/NeoGenomics (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Guardant Health; Janssen; MSD Oncology; Roche; Sanofi
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; emd serono; Jazz Pharmaceuticals; Merck; novartis; nuvation bio; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Elena Elimova
Employment - Merck (I)
Honoraria - Daiichi Sankyo/Astra Zeneca; Roche Canada
Consulting or Advisory Role - Abbvie; Adaptimmune (Inst); Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Signatera; Viracta Therapeutics; Zymeworks (Inst)
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca Canada (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Zymeworks (Inst)
 
Adrian Sacher
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridgebio (Inst); CRISPR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Genentech/Roche; Merck
(OPTIONAL) Uncompensated Relationships - Amgen; Genentech/Roche; Merck